Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GSK
stocks logo

GSK

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
7.92B
+0.46%
1.151
+3.29%
8.23B
+2.73%
1.335
+3.31%
8.45B
+4.12%
0.660
+13.94%
Estimates Revision
The market is revising Downward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by -1.74% over the past three months. During the same period, the stock price has changed by 3.47%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.74%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.39%
In Past 3 Month
Stock Price
Go Up
up Image
+3.47%
In Past 3 Month
2 Analyst Rating
down Image0
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 40.13 USD with a low forecast of 35.25 USD and a high forecast of 45.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
down Image0
Current: 40.860
sliders
Low
35.25
Averages
40.13
High
45.00
down Image0
Current: 40.860
sliders
Low
35.25
Averages
40.13
High
45.00
Jefferies
Peter Welford
Strong Buy
to
Hold
Downgrades
n/a
2024-11-12
Reason
Jefferies
Peter Welford
Price Target
n/a
2024-11-12
Downgrades
Strong Buy
to
Hold
Reason
Jefferies analyst Peter Welford downgraded GSK to Hold from Buy with a price target of $39.50, down from $53. The firm finds it "frustrating" that despite the favorable Zantac settlement, robust performance of GSK's Specialty unit, and pipeline successes, the shares "continue to languish." While GSK's fundamental value remains compelling, overhangs for the company's Arexvy and Shingrix vaccines, "more subdued" 2025 growth, and few near-term catalysts to "rebuild belief" suggests the stock's value disconnect may persist, the analyst tells investors in a research note.
Guggenheim
Seamus Fernandez
Strong Buy
to
Hold
Downgrades
n/a
2024-10-31
Reason
Guggenheim
Seamus Fernandez
Price Target
n/a
2024-10-31
Downgrades
Strong Buy
to
Hold
Reason
Guggenheim analyst Seamus Fernandez downgraded GSK to Neutral from Buy without a price target following the Q3 report. While the company's guidance appears achievable and it is a "reasonable defensive pharma to own" with a low multiple and solid dividend, limited upside in pipeline catalysts and 2025 estimates "makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves materially," the analyst tells investors in a research note.
UBS
Jo Walton
Strong Buy
to
Hold
Downgrades
n/a
2024-07-08
Reason
UBS
Jo Walton
Price Target
n/a
2024-07-08
Downgrades
Strong Buy
to
Hold
Reason
Jefferies
Peter Welford
Strong Buy
Maintains
$53 → $53
2024-07-02
Reason
Jefferies
Peter Welford
Price Target
$53 → $53
2024-07-02
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 0.00, compared to its 5-year average forward P/E of 10.89. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
10.89
Current PE
0.00
Overvalued PE
13.92
Undervalued PE
7.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
8.43
Current EV/EBITDA
6.70
Overvalued EV/EBITDA
10.25
Undervalued EV/EBITDA
6.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.09
Current PS
1.87
Overvalued PS
2.43
Undervalued PS
1.75

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GSK News & Events

Events Timeline

(ET)
2025-06-13
06:26:00
GSK's RSV vaccine accepted for regulatory review by EMA for expanded use
select
2025-06-12 (ET)
2025-06-12
12:40:51
Senators to propose ban on drug ads to consumers, WSJ reports
select
link
2025-06-12
06:11:57
GSK licenses Shigella vaccine candidate to Bharat Biotech
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-13SeekingAlpha
PinnedGSK’s RSV vaccine to be reviewed by the EU for expanded use in adults

  • GSK's Vaccine Expansion: GSK plc announced that the European Medicines Agency has accepted its application to expand the use of its respiratory syncytial virus vaccine for adults aged 18 and older, with a regulatory decision expected in the first half of 2026.

  • Global Indications: The company is also pursuing expanded indications for its RSV vaccine in other regions, including the United States and Japan.

Preview
8.0
06-13SeekingAlpha
Measles cases in U.S. reach nearly 1,200

  • Current Measles Outbreak in the U.S.: The CDC reports 1,197 confirmed measles cases across 34 states in 2025, with 21 outbreaks and three related deaths so far this year.

  • Vaccination Recommendations: The CDC advises the two-dose MMR vaccine to prevent measles and mitigate severity for those exposed, with Merck and GSK being the primary vaccine providers in the U.S.

Preview
9.0
06-13Benzinga
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up

  • FDA Approval: The FDA has expanded the approval of Moderna's RSV vaccine to adults aged 18-59 at increased risk for the disease, based on positive trial results showing significant immune responses and a favorable safety profile.

  • Advisory Committee Changes: Health Secretary Robert F. Kennedy Jr. appointed new members to the CDC’s Advisory Committee on Immunization Practices, including critics of mRNA vaccines, while dismissing all previous members to restore public confidence in vaccine science amid ongoing regulatory uncertainties.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GSK plc (GSK) stock price today?

The current price of GSK is 40.86 USD — it has decreased -3.84 % in the last trading day.

arrow icon

What is GSK plc (GSK)'s business?

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

arrow icon

What is the price predicton of GSK Stock?

Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 40.13 USD with a low forecast of 35.25 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GSK plc (GSK)'s revenue for the last quarter?

GSK plc revenue for the last quarter amounts to 9.46B USD, increased 1.33 % YoY.

arrow icon

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

GSK plc. EPS for the last quarter amounts to 0.49 USD, increased 53.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

The market is revising Downward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by -1.74% over the past three months. During the same period, the stock price has changed by 3.47%.
arrow icon

How many employees does GSK plc (GSK). have?

GSK plc (GSK) has 70212 emplpoyees as of June 14 2025.

arrow icon

What is GSK plc (GSK) market cap?

Today GSK has the market capitalization of 83.69B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free